Title: siRNA Targeting Myeloid Cell Leukemia Sequence 1
Number: 7,514,550
Filed: Sept. 20, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."
Title: Tumor Inhibition by Modulating Sprouty Expression or Activity
Number: 7,514,549
Filed: April 17, 2006
Lead Inventor: Justin McCormick, Michigan State University
The patent, its abstract states, claims "methods … for identifying compounds that decrease the expression or activity of an over-expressed Sprouty protein in certain cancers. Such compounds can be useful for treating cancers in which a Sprouty protein is over-expressed. Also provided are therapeutic formulations and pharmaceutical formulations [comprising an siRNA] for treating cancers characterized by over-expression of a Sprouty protein."
Title: Methods of Inhibiting COX-2
Number: 7,514,548
Filed: Aug. 1, 2005
Lead Inventor: Douglas Trask, University of Iowa
The invention, the patent's abstract states, comprises "RNA molecules [such as] antisense, RNAi, or siRNA … specific for COX-2, and further provides methods of reducing expression of COX-2 in cells, [for example], cancer cells."
Title: Carrier Peptide for Delivering siRNA in Mammalian Cells
Number: 7,514,530
Filed: April 26, 2004
Lead Inventor: Gilles Divita, Centre National de la Recherche Scientifique
The invention, the patent's abstract states, comprises a peptide carrier and an "appropriate siRNA … selected to silence a target mRNA."
Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules
Number: 7,514,099
Filed: Feb. 14, 2006
Lead Inventor: Tongqian Chen, Sirna Therapeutics (Merck)
According to the patent's abstract, the invention "relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules … [and] also features compositions and methods of use for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity in a subject or organism.
"Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles, and transfection agents that effectively transfect or deliver biologically active molecules, such as … dsRNA … and small nucleic acid molecules … to relevant cells and/or tissues, such as in a subject or organism. Such novel cationic lipids, microparticles, nanoparticles, and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism. The compositions described … are generally referred to as formulated molecular compositions or lipid nanoparticles," the abstract states.
Title: Self-Complementary AAV-Mediated Delivery of Interfering RNA Molecules to Treat or Prevent Ocular Disorders
Number: 20090087413
Filed: Oct. 1, 2008
Inventor: Allan Shepard, Alcon
"The invention provides methods for delivering interfering RNA molecules to an eye of a patient to treat ocular disorders," the patent application's abstract states. "In particular, the methods of the invention comprise the use of a self-complementary adeno-associated viral vector that can deliver an interfering RNA molecule to an eye of a patient to inhibit expression of a gene that is associated with an ocular disorder."
Title: Two-Color Real-Time/End-Point Quantitation of microRNAs
Number: 20090087858
Filed: Dec. 8, 2008
Lead Inventor: Andrew Finn, Applied Biosystems
The invention, the patent application's abstract states, "is directed to methods, reagents, kits, and compositions for detecting target polynucleotide sequences, especially small target polynucleotides such as miRNAs, between two samples. A pair of linker probes can be employed in two different reactions to query a particular species of target polynucleotide. A pair of detector probes, a single forward primer specific for the target polynucleotide, and a reverse primer can be employed in an amplification reaction to query the difference in expression level of the target polynucleotide between the two samples.
"In some embodiments a plurality of small miRNAs are queried with a plurality of linker probes," the abstract adds. "The plurality of queried miRNAs can then be decoded in a plurality of amplification reactions."
Title: Primer Extension-Based Method for the Generation of siRNA/miRNA Expression Vectors
Number: 20090087910
Filed: Aug. 15, 2008
Lead Inventor: Lin Liu, Oklahoma State University
"Functional shRNA is produced from an expression vector prepared by selecting a two primer design in which the primers are less than about 50 nucleotides in length, annealing and extending the primers using primer extension, digesting the primer extension product and inserting the digestion product into a suitable vector," the patent application's abstract states. "When the shRNA vectors are inserted into a cell, shRNA transcribed from the vectors modulates gene activity within the cell."
Title: siRNA Targeting Transducin Beta-Like 3
Number: 20090088563
Filed: Oct. 14, 2008
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TBL3."